Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (371-380 of 471) with videos related to

Pageof 48
Sort By:
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 2, 2021
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood Cancer Journal|May 8, 2020
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?M Hasib Sidiqi, Mohammed Aljama, Shaji K Kumar, et al.
Pageof 48

Showing results (371-380 of 471) with videos related to

Sort By:
Pageof 48
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 2, 2021
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemiaSaurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, et al.
Research Square|March 27, 2026
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple MyelomaNadine Abdallah, Byron Smith, Thomas White, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 31, 2019
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomesJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood Cancer Journal|May 8, 2020
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?M Hasib Sidiqi, Mohammed Aljama, Shaji K Kumar, et al.
Pageof 48